Caribou Biosciences to Halt Drug Programs, Review Strategic Options

Caribou Biosciences announced it will evaluate strategic alternatives and discontinue its vispa-cel and CB-011 allogeneic CAR-T programs. As of June 30, 2026, the company reported $113.8 million in cash, cash equivalents, and marketable securities.